Seagen-Merck Bladder Cancer Treatment Shows Positive Results; Seagen Shares Jump
Biotechnology company Seagen Inc. (SGEN) and Tokyo-based Astellas Pharma Inc. on Friday reported positive results from a Phase 3 trial of their experimental bladder cancer medicine, Padcev, in comb...
Drugmaker Merck says Keytruda combination fails in lung cancer trial
Merck said on Friday its cancer immunotherapy Keytruda in combination with partner Eisai's drug failed to meet main goals in a late-stage study evaluating it as a treatment for patients with a type...
Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag
The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.
Frontier portfolio company signs collaboration deal with Merck
Frontier IP Group PLC (AIM:FIPP), a firm specialising in the commercialisation of intellectual property, announced in an RNS today that its portfolio company Exscientia has entered into a collabora...
Merck: A Blue-Chip Dividend Stock Worth Buying
Merck & Co., Inc.'s payout ratios suggest that the market-beating dividend is well-covered. The company's stacked portfolio of therapies and candidates should lead to solid growth moving forward. M...
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.
Merck: Secure A Safe 8% Annualized Return For The Next Decade
Merck's strong performance in the past two years, driven by Keytruda and Lagevrio, has outperformed the market by an impressive 52%. MRK's acquisition of Prometheus Biosciences signals its effort t...
Merck (MRK) Gets CHMP Nod for Keytruda in Adjuvant Lung Cancer
Merck's (MRK) Keytruda gets a positive CHMP opinion, recommending the approval of the drug for the adjuvant treatment of adults with non-small cell lung cancer, who are at high risk of recurrence, ...
Merck's (MRK) Ebola Vaccine Gets Approval for Kids in Europe
The European Commission approves Merck's (MRK) Ebola vaccine for use in children as young as one year.
Merck & Co., Inc. (MRK) Citi 18th Annual BioPharma Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK ) Citi 18th Annual BioPharma Conference September 6, 2023 1:50 PM ET Company Participants Marjorie Green - SVP and Head of Late Stage Oncology, Global Clinical Developme...
Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference.
Why Is Merck (MRK) Up 4.3% Since Last Earnings Report?
Merck (MRK) reported earnings 30 days ago. What's next for the stock?
Merck's (MRK) Keytruda Receives EU Nod in Gastric Cancer
Following the approval, Merck's (MRK) Keytruda is the first immunotherapy approved in the EU for first-line treatment for HER2-positive advanced gastric cancer in adults whose tumors express PD-L1.
Merck (MRK), Eisai to End Keytruda-Lenvima Combo Cancer Study
With the phase III LEAP-010 study failing to show an overall survival benefit for patients with recurrent or metastatic HNSCC, Merck (MRK) and Eisai have decided to close the study.
Will Keytruda Remain Merck's (MRK) Key Top-Line Driver?
With continued label expansion into new indications, particularly earlier-line launches, Merck's (MRK) Keytruda is expected to remain a key top-line driver.
Related Companies